Uric acid
产品说明书
 |
同义名 : | - |
| CAS号 : | 69-93-2 | |
| 货号 : | A744554 | |
| 分子式 : | C5H4N4O3 | |
| 纯度 : | 98% | |
| 分子量 : | 168.11 | |
| MDL号 : | MFCD00005712 | |
| 存储条件： |
Pure form Sealed in dry,2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Uric acid acts as a scavenger of oxygen radicals and is a crucial antioxidant that helps maintain blood pressure stability and manage oxidative stress. It effectively removes reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, thus preventing lipid peroxidation[1].[2]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00664144 | Hyperuricemia | Phase 2 | Terminated(due to poor enrollm... 展开 >>ent) 收起 << | - | Belgium ... 展开 >> Sanofi-Aventis Administrative Office Diegem, Belgium France Sanofi- Aventis Administrative Office Paris, France Germany Sanofi-Aventis Administrative Office Berlin, Germany Italy Sanofi-Aventis Administrative Office Milan, Italy 收起 << |
| NCT00477789 | Chronic Heart Failure | Phase 4 | Completed | - | Italy ... 展开 >> Division of Cardiology, University Hospital of Verona Verona, Italy, 37129 收起 << |
| NCT00290992 | Nutritional and Metabolic Dise... 展开 >>ases 收起 << | Phase 2 | Completed | - | Japan ... 展开 >> Sanofi-Aventis Tokyo, Japan 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
5.95mL 1.19mL 0.59mL |
29.74mL 5.95mL 2.97mL |
59.48mL 11.90mL 5.95mL |
| 参考文献 |
|---|